Enanta制药

ENTA NASDAQ
89.14
+3.33
+3.88%
盘后: 89.14 0 0.00% 16:48 06/17 EDT
开盘
86.29
昨收
85.81
最高
90.35
最低
85.15
成交量
35.86万
成交均量(3M)
19.10万
52周最高
127.77
52周最低
64.09
换手率
1.82%
市值
17.53亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Enanta制药 ENTA股票价格,Enanta制药股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.
展开 >

最近浏览

名称
价格
涨跌幅